Academic Journal
Entrectinib in ROS1 -positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial
| العنوان: | Entrectinib in ROS1 -positive advanced non-small cell lung cancer: the phase 2/3 BFAST trial |
|---|---|
| المؤلفون: | Dziadziuszko, Rafal, Archer, Venice, Assaf, Zoe June, Diarra, Cheick, Bhagawati-Prasad, Vijay, Mathisen, Michael, Maclennan, Margaret, Shagan, Sarah M., Nersesian, Rhea, Tanaka, Tomohiro, Moskovitz, Mor, Yu, Chong-Jen, Chiu, Chao-Hua, Sugawara, Shunichi, Cadranel, Jacques, Swalduz, Aurelie, KILIÇKAP, SAADETTİN, Nadal, Ernest, Mok, Tony, Gadgeel, Shirish M., Peters, Solange |
| سنة النشر: | 2024 |
| الوصف: | Although comprehensive biomarker testing is recommended for all patients with advanced/metastatic non-small cell lung cancer (NSCLC) before initiation of first-line treatment, tissue availability can limit testing. Genomic testing in liquid biopsies can be utilized to overcome the inherent limitations of tissue sampling and identify the most appropriate biomarker-informed treatment option for patients. The Blood First Assay Screening Trial is a global, open-label, multicohort trial that evaluates the efficacy and safety of multiple therapies in patients with advanced/metastatic NSCLC and targetable alterations identified by liquid biopsy. We present data from Cohort D (ROS1-positive). Patients >= 18 years of age with stage IIIB/IV, ROS1-positive NSCLC detected by liquid biopsies received entrectinib 600 mg daily. At data cutoff (November 2021), 55 patients were enrolled and 54 had measurable disease. Cohort D met its primary endpoint: the confirmed objective response rate (ORR) by investigator was 81.5%, which was consistent with the ORR from the integrated analysis of entrectinib (investigator-assessed ORR, 73.4%; data cutoff May 2019, >= 12 months of follow-up). The safety profile of entrectinib was consistent with previous reports. These results demonstrate consistency with those from the integrated analysis of entrectinib in patients with ROS1-positive NSCLC identified by tissue-based testing, and support the clinical value of liquid biopsies to inform clinical decision-making. The integration of liquid biopsies into clinical practice provides patients with a less invasive diagnostic method than tissue-based testing and has faster turnaround times that may expedite the reaching of clinical decisions in the advanced/metastatic NSCLC setting. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1038/s41591-024-03008-4 |
| الاتاحة: | https://doi.org/10.1038/s41591-024-03008-4 https://avesis.hacettepe.edu.tr/publication/details/5eb56e55-7a41-4633-97e7-de7e7002c7c8/oai |
| Rights: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.3251A1A5 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41591-024-03008-4 |
|---|